How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)

Simply Wall St.10-08

Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvements and a generally well tolerated safety...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2673108210?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-08 03:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673108210","market":"sg","top_or_hot":-1,"title":"How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)","media":"Simply Wall St.","content":"<div>\n<p>Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvements and a generally well tolerated safety...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/how-positive-lupus-trial-data-will-impact-biogen-stock-biib\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-08 03:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/how-positive-lupus-trial-data-will-impact-biogen-stock-biib><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvements and a generally well tolerated safety...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/how-positive-lupus-trial-data-will-impact-biogen-stock-biib\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EETH","symbol_name":"以太币期货ETF-ProShares","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/how-positive-lupus-trial-data-will-impact-biogen-stock-biib","article_id":"2673108210","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/how-positive-lupus-trial-data-will-impact-biogen-stock-biib","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2673108210","pubTimestamp":1791401186,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvements and a generally well tolerated safety profile across 93 adults who had limited benefit from standard antimalarials.\nThe litifilimab data extends to a full year of follow up, with once monthly dosing, Breakthrough Therapy Designation, and rapid responses in placebo crossover patients that collectively point to a targeted autoimmune...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EETH":"以太币期货ETF-ProShares","VOTE":"TCW Transform 500 ETF","BK4139":"生物科技","LU0234570918.USD":"高盛全球核心股票组合Acc Close","ETQ":"T-Rex 2X Inverse Ether Daily Target ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","ETCO":"Grayscale Ethereum HIGH Income ETF","TETH":"21Shares Ethereum ETF","QETH":"以太坊ETF-Invesco Galaxy","BMED":"iShares Health Innovation Active ETF","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","ESK":"REX-Osprey ETH + Staking ETF","YETH":"Roundhill Ether Covered Call Strategy ETF","ETHT":"ProShares Ultra Ether ETF","GXDW":"Global X Dorsey Wright Thematic ETF","ETU":"T-Rex 2X Long Ether Daily Target ETF","RGLO":"Global Equity Active ETF","SETH":"1倍做空以太币期货ETF-Proshares","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","ETHU":"2倍以太币期货ETF-Volatility Shares","ETHV":"以太坊ETF-VanEck","BK4588":"碎股","VGFPF":"Vanguard Funds PLC","BIIB":"渤健公司","ETH":"低成本以太坊ETF-Grayscale","BK4601":"加密货币现货ETF","ETHW":"以太坊ETF-Bitwise","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","ETHA":"以太坊ETF-iShares","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","FETH":"以太币ETF-Fidelity","PMDE":"PGIM S&P 500 Max Buffer ETF - December","JOYT":"JPMorgan Equity and Options Total Return ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","ETHD":"ProShares UltraShort Ether ETF","BK4532":"文艺复兴科技持仓","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","EZET":"以太坊ETF-Franklin","ETHE":"最大以太坊ETF-Grayscale","BK4585":"ETF&股票定投概念"},"translate_title":"积极的狼疮试验数据将如何影响百健股票 (BIIB)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETHD":0.6,"EETH":0.6,"ETHA":0.6,"EZET":0.6,"PBE":0.6,"GXDW":0.74,"JOYT":0.74,"YETH":0.6,"VOTE":0.74,"ETQ":0.6,"ETHW":0.6,"FEBU":0.74,"VGFPF":0.74,"ETCO":0.6,"BIIB":1.5,"RGLO":0.74,"ESK":0.6,"SETH":0.6,"PMDE":0.74,"ETHV":0.6,"TETH":0.6,"ETU":0.6,"ETHE":0.6,"QETH":0.6,"ETHU":0.6,"FETH":0.6,"BMED":0.6,"ETHT":0.6,"ETH":0.74,"DECU":0.74},"content_text":"Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvements and a generally well tolerated safety profile across 93 adults who had limited benefit from standard antimalarials. The litifilimab data extends to a full year of follow up, with once monthly dosing, Breakthrough Therapy Designation, and rapid responses in placebo crossover patients that collectively point to a targeted autoimmune opportunity alongside Biogen’s broader neurology and immunology portfolio. We will now look at how Biogen’s broader investment narrative could be influenced by litifilimab’s year long Phase 2 CLE data.  Scan beyond Biogen and spot other potential breakout healthcare stories using our carefully filtered list of 34 healthcare AI stocks before the next wave of clinical readouts hits the market. AdvertisementBiogen Investment Narrative Recap To own Biogen, you need to believe the pivot from a shrinking multiple sclerosis base to a broader neurology and immunology portfolio can keep earnings growing while cost discipline holds. The AMETHYST litifilimab data helps that story at the margin, but the near term spotlight still sits on execution in Alzheimer’s, rare disease and recently acquired assets. The biggest near term swing factor is how effectively Biogen ramps newer launches such as LEQEMBI, SKYCLARYS and ZURZUVAE while keeping core operating expenses around the guided US$2.65b to US$2.7b. The largest risk remains that multiple sclerosis erosion, margin pressure from one off charges and financing costs outpace contributions from this growth portfolio. The 52 week AMETHYST litifilimab update matters most when set against Biogen’s upcoming late stage lupus catalysts. Management plans to release two Phase 3 datasets for litifilimab in systemic lupus erythematosus in Q4 2026. The CLE data does not change that timeline, but it gives investors more operational evidence that the mechanism can sustain efficacy and remain manageable on safety. If those Phase 3 lupus readouts are positive, litifilimab could deepen Biogen’s push into immunology alongside nephrology and complement programs such as EMPAVELI. If they disappoint, the business leans even harder on LEQEMBI and the broader growth portfolio to offset pressure from multiple sclerosis and restructuring costs, keeping execution risk front and center. What The Litifilimab Data Means For Biogen's Consensus Story Biogen's narrative projects US$11.0b revenue and US$2.2b earnings by 2029. This assumes 3.3% yearly revenue growth and an earnings increase of about US$1.4b from US$834.6m today. Litifilimab slots into an analyst model that already assumes modest 3.3% annual top line growth and a sharp step up in profit margins from 8.3% today to 20.1% in three years. The AMETHYST cutaneous lupus erythematosus readout does not rewrite those numbers. It instead supports the idea that Biogen can add another immunology pillar that helps management work toward the US$2.2b earnings target by 2029 without relying on any single launch to carry the whole neurology and immunology effort. Consensus forecasts imply earnings climbing from US$834.6m today to US$2.2b by around 2029, with some analysts as high as US$3.3b and others closer to US$1.7b. That spread indicates sentiment on execution risk is wide. A clean Phase 3 lupus outcome for litifilimab could reduce some of that disagreement by giving investors more line of sight on a potential new earnings contributor in the back half of this decade. On those numbers, Biogen would need to support a P/E of 20.4x on 2029 earnings, down from 40.2x today but still above the 17.1x level cited for the broader US biotech group. The current share price of US$227.07 sits only 4.7% below the US$238.18 consensus target, which suggests the market already reflects a fair amount of confidence that the growth portfolio, including litifilimab, can collectively offset multiple sclerosis pressure and one off restructuring and financing costs. Uncover why Biogen's fair value indicates a 7% potential upside to its current price that may not last much longer. NasdaqGS:BIIB 1-Year Stock Price Chart Exploring Other Perspectives One alternate view on Biogen leans hard into litifilimab as a catalyst. In that version, the most optimistic analysts were already pencilling in US$11.8b of revenue and US$3.3b of earnings by 2029, before these 52 week CLE data. You now have a live example of how sharply expectations can differ, so explore both camps and decide which narrative feels closer to your own view. Explore 4 other Biogen fair value estimates, including one that suggests as much as 100% upside from the current price. Reach Your Own Conclusion Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Biogen. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Biogen's overall financial health at a glance.  Looking for more Biogen sized investment ideas? If Biogen is already on your radar, it can help to line it up against other stocks with very different drivers, risk profiles and income potential using the Simply Wall St Screener.  For investors hunting for value with quality behind it, scan through our 27 high quality undervalued stocks that combine healthy fundamentals with more modest pricing. If capital preservation and steadier price moves matter most to you, focus on our 31 resilient stocks with low risk scores that screen for businesses with more resilient risk scores. When you want growth potential but prefer to avoid the most heavily followed tickers, cast a wider net using our 19 high quality undiscovered gems that highlight under the radar companies with solid underlying numbers.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2673108210","isCrawlerRequest":true}